Jefferies reiterates Discovery Labs at buy

Discovery Laboratories was reiterated at a buy rating and a $10 price target by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies expects the stock to trade higher on expected Surfaxin approval. The drug, for bronchopulmonary dysplasia, was granted fast track status by the Food and Drug Administration. Shares of the Warrington, Pa., biopharmaceutical company were up 31 cents, or 4.13%, at $7.82 on volume of 1,469,777 shares versus the three-month running average of 447,488 shares. (Nasdaq: DSCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.